填补临床空白！晚期HER2阳性胃癌患者迎来靶向治疗新希望

Core Insights - Gastric cancer remains one of the most prevalent malignant tumors in China, with high incidence and mortality rates, particularly affecting patients diagnosed at advanced stages [1] - The approval of the targeted antibody-drug conjugate, Derdumumab, for treating HER2-positive gastric cancer fills a significant gap in second-line treatment options, offering new hope for patients [1] Group 1: Treatment Efficacy - The DESTINY-Gastric04 clinical trial demonstrated that Derdumumab reduces the risk of death by 30% compared to traditional treatments, extending median survival to 14.7 months, an increase of nearly 3 months [2] - The two-year survival rate doubled, with an objective response rate of 44.3%, including 7 patients achieving complete response, and a disease control rate of 91.9% [2] Group 2: Safety and Clinical Impact - The safety profile of Derdumumab is manageable, with no new safety issues reported, making it a viable option for patients [2] - The approval of this drug marks a new era in precision targeted therapy for second-line HER2-positive gastric cancer, potentially extending innovative treatment strategies to earlier stages of the disease [2]